We are live on ! Find out more
XTNT icon

Xtant Medical Holdings

18 hedge funds and large institutions have $6.22M invested in Xtant Medical Holdings in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more capital invested

Capital invested by funds: $4.02M → $6.22M (+$2.2M)

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

0.58% more ownership

Funds ownership: 92.33%92.91% (+0.58%)

0% more funds holding

Funds holding: 1818 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Holders
18
Holders Change
Holders Change %
0%
% of All Funds
0.31%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
4
Reduced
3
Closed
3
Calls
Puts
Net Calls
Net Calls Change

XTNT Hedge Fund Activity: Q3 2022 in Review

18 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Xtant Medical Holdings (XTNT) for Q3 2022, worth a combined $6.22M — up 55% from $4.02M a quarter earlier.

Fund positioning in XTNT was balanced in Q3 2022: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 3 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $612K. The largest seller was Bridgeway Capital Management, cutting an estimated $127K.

  • 18 institutional investors held Xtant Medical Holdings (XTNT) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $6.22M of Xtant Medical Holdings stock for Q3 2022, up 55% quarter-over-quarter.
  • 3 funds opened new Xtant Medical Holdings positions in Q3 2022 and 3 closed out, a net change of 0 holders.
  • The largest Xtant Medical Holdings buyer in Q3 2022 was Vanguard Group, an estimated $612K added.
  • The largest Xtant Medical Holdings seller in Q3 2022 was Bridgeway Capital Management, an estimated $127K sold.

Based on aggregated 13F filings for Q3 2022.